The synergy witnessed following SLN administration partly arises from the presence of a subset of tumor-infiltrating T lymphocytes that express both PD-1 and CD137 on their surface, leading to enhanced efficacy when targeting both receptors.84 The gene discussed is PDCD1; the disease is neoplasm.